Login to Your Account



Clinic Roundup


Friday, November 9, 2012
• Cellceutix Corp., of Beverly, Mass., said patient dosing was initiated in a Phase I trial with Kevetrin, its anti-cancer drug candidate, at Harvard University's Dana Farber Cancer Center and Beth Israel Deaconess Medical Center.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription